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ABSTRACT
Background C-reactive protein (CRP) levels reflect 
ongoing inflammation and/or tissue damage, and studies 
suggest that platelets play a role in tumor invasion and 
metastasis. P-CRP is defined as the multiplied product 
of serum CRP and platelet levels. Here the prognostic 
value of pre- and post-operative P-CRP levels in pan-
creatic cancer (PC) patients was assessed.
Methods This retrospective study used data from 
107 consecutive PC patients who had undergone either 
pancreaticoduodenectomy or distal pancreatectomy. 
Clinicopathological parameters and pre/post-operative 
laboratory data derived from patient records were used 
for analyses. P-CRP was defined as the product of 
peripheral thrombocyte count (/uL) × serum CRP level 
(mg/dL) divided by 104; the optimal P-CRP cut-off value 
was defined using receiver operating characteristic 
curves.
Results PC patients were classif ied as either 
P-CRPLow (< 1.782; n = 49) or P-CRPHigh (≥ 1.782; n 
= 58), based on the cut-off value of 1.782. Univariate 
analysis revealed that performance status, clinical stage, 
pathological T and N stages, P-CRP, and carbohydrate 
antigen 19-9 (CA19-9) significantly affected overall 
survival (OS). Multivariate analysis revealed that inde-
pendent risk factors for OS were pathological N stage, 
P-CRP, and CA19-9. Additionally, 103 PC patients for 
whom postoperative data were available were classi-
fied into four groups (P-CRPLow-Down, P-CRPLow-Up, 
P-CRPHigh-Down and P-CRPHigh-Up), based on preopera-
tive P-CRP and postoperative trend of P-CRP, and we 
found that prognosis, in terms of OS, was significantly 
different among these groups (P = 0.012).
Conclusion Pre- and post-operative P-CRP values are 
a potential predictor of prognosis in PC patients.
Key words CRP; pancreatic cancer; platelet; prognosis
Despite advances in the treatment and care for pan-
creatic cancer (PC), prognosis remains poor as 5-year 
survival is less than 10%,1 and multidisciplinary strate-
gies for diagnosis and treatment have been evaluated 
to improve outcomes.2, 3 The relationship between 
tumorigenesis and inflammation has been known ever 
since Rudolf Virchow first reported the presence of 
leukocytes within tumors in the 19th century,4 while 
the underlying molecular mechanisms continue to be 
elucidated.5 Consistent with this, it is known that PC 
development requires a certain type of inflammation in 
the microenvironment,6 e.g. pancreatic satellite cells,7–9 
and currently, inflammation is known to be an impor-
tant hallmark of malignancy.
In recent years, several indicators based on com-
mon inflammatory factors such as CRP, platelets and 
leukocytes have been reported to have prognostic 
value in various human tumors.10–12 While these 
indicators have the advantage of simplicity of evalu-
ation, the mechanism (or mechanisms) by which they 
affect tumorigenesis have not been described in detail. 
Nonetheless, a potential common mechanism underly-
ing the prognostic impact of these indicators may be an 
association with systemic and/or local inflammation. 
Over the past few years, it has been widely known 
that inflammation caused by several sources plays a 
critical role in tumorigenesis. For examples in the gas-
trointestinal field, Helicobacter pylori infection leads 
to chronic gastritis and gastric cancer,13, 14 and chronic 
HBV/HCV infection increases the risk of hepatocellular 
carcinoma.15 Recently, the molecular pathways and 
mechanisms by which inflammation induces tumori-
genesis have been partially elucidated and they appear 
to be mediated through proteins such as NF-κB and 
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STAT3.16 Particularly, PC development is involved with 
a certain type of inflammation in the microenvironment 
of cancer.6, 8
CRP is predominantly produced by the liver in 
response to an inflammatory stimulus that involves 
increased cytokine expression; and serum CRP value 
reflects ongoing inflammation and/or tissue damage.17 
Interestingly, while one study has demonstrated that 
human CRP activation itself is one of the mediators 
of tissue injury,18 it is not known if CRP has a direct 
molecular role in tumor progression.
Platelets (also called thrombocytes), are a compo-
nent of blood whose function is to initiate blood clot 
formation. In the process of inflammation, it is known 
that platelets are exposed to soluble mediators such as 
lipid mediators, cytokines and chemokines released by 
activated leucocytes, endothelial cells and perivascular 
cells.19 Importantly, platelets are an important source 
of cytokines that enhance tumor angiogenesis; this 
concurs with the fact that thrombocytopenic mice are 
protected against metastasis, which was established as 
early as 1968.20 Labelle et al. have reported that platelets 
co-cultured with breast carcinoma cells induce cancer 
stemness.21 They demonstrate further that platelets 
promote both TGF-β and NFκ-B pathways, inducing 
an epithelial-to-mesenchymal transition (EMT) in 
breast and colon carcinoma cell lines, thus, facilitating 
a metastatic phenotype. In addition to the above, they 
are known to release multiple factors that play a role in 
tumor invasion and metastasis.22 Furthermore, clinical 
studies have demonstrated that a high platelet count is 
associated with increased mortality in a variety of can-
cers, including gynecological malignancies and lung, 
renal, gastric, colorectal, and breast cancers.23–30
Recently, an index calculated using platelet count 
and C-reactive protein (CRP) levels has been reported 
as a prognostic factor in PC, and P-CRP value, whose 
calculation is based on measured values of platelets and 
CRP [peripheral thrombocyte count (/uL) × serum CRP 
level (mg/dL) divided by 104], has also been reported as 
a prognostic indicator in gastric cancer.31
P-CRP value is a simple multiplied product of the 
measured values of platelets and CRP. In gastric cancer 
patients, P-CRP value is a known synergistic prognostic 
indicator whose importance is emphasized more than 
that of either CRP or platelet levels alone.31
However, as these previous studies had focused on 
the patient’s condition before surgery only, the prognos-
tic potential of postoperative P-CRP and its relationship 
with preoperative values remains unclear. Thus, this 
retrospective study investigated the prognostic value of 
pre- and post-operative P-CRP values in PC patients.
MATERIALS AND METHODS
Patients
Between August 2005 and August 2016, 107 consecu-
tive PC patients underwent pancreatic resection at the 
Tottori University Hospital (Yonago, Japan) and were 
included in this retrospective study. All patients under-
went either pancreaticoduodenectomy (PD) or distal 
pancreatectomy (DP) by open laparotomy. Surgeons 
with substantial hepato-biliary-pancreatic surgical 
expertise performed all the procedures at the Tottori 
University Hospital. PC patients were classified by 
clinical symptom and pathological detection according 
to 7th edition of the Union for International Cancer 
Control (UICC) TNM staging system. The study proto-
col was approved by the ethical review board of Tottori 
University (approval number: 17A135).
Parameters
The clinicopathological parameters and laboratory 
data of all patients were extracted from the electronic 
medical records. These included patient characteristics 
such as age, gender, body mass index (BMI), Eastern 
Cooperative Oncology Group (ECOG) performance 
status (PS), tumor location, preoperative biliary 
infection, neoadjuvant chemotherapy (NAC), UICC 
stage, histological type, T/N stages, vascular invasion, 
perineural invasion, and lymphatic vessel invasion and 
surgical and postoperative parameters such as adjuvant 
chemotherapy(AC), operation time, blood loss volume, 
portal vein resection (PVR), R0 resection, postop-
erative pancreatic fistula (POPF), and postoperative 
complications.
Postoperative complications that occurred within 
30 days were evaluated using the Clavien-Dindo (CD) 
classification system.32 POPF was assessed according to 
consensus guidelines issued by the International Study 
Group of Pancreatic Fistula.33
The P-CRP value was defined as the product of 
peripheral thrombocyte count (/uL) × serum CRP level 
(mg/dL) divided by 104.The optimal cut-off value was 
defined based on the receiver operating characteristic 
(ROC) curve for P-CRP that included data on two-year-
survival after either PD or DP.
Follow-up
After the operation, all the patients had regular follow-
ups to obtain their survival data by means of retrieving 
medical records, and communication by mail and 
telephone. Postoperative P-CRP values were checked 
with PC patients during their first visits after discharge, 
which was approximately 1 month later.
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Statistical analysis
Continuous variables were reported as means and stan-
dard deviations, while categorical data were reported as 
proportions (%). Univariate analyses were performed 
using Fisher’s exact test for categorical variables, and 
Mann-Whitney U-test for continuous variables. Cox 
proportional hazard model was used to calculate the 
hazard ratios for multivariate analysis. All statistical 
analyses were performed using the statistical software 
SPSS v. 23.0 statistical software (IBM Corporation, 
Armonk, NY), and P values less than 0.05 were consid-
ered statistically significant.
RESULTS
Table 1 summarizes all patient characteristics. Using 
preoperative laboratory data, the cut-off value of P-CRP 
was determined to be 1.782 (area under the curve, AUC 
= 0.67), and additionally, CRP and platelet values were 
also analyzed by ROC curves (AUC = 0.66 and 0.51, 
respectively; Fig. 1). In addition, we analyzed CA19-9, 
which has been reported to be one of the prognostic 
markers of pancreatic cancer, by ROC curve (AUC 
= 0.73). Then, all PC patients were classified into 
P-CRPLow (< 1.782) group (n = 49) and P-CRPHigh (≥ 
1.782) group (n = 58) according to the cut off value.
Table 2 shows the comparison of clinicopatho-
logical factors between the P-CRPLow and P-CRPHigh 
groups. Operation time and blood loss had significant 
differences between P-CRPLow and P-CRPHigh groups, 
while other factors including preoperative biliary infec-
tion did not significantly differ between the two groups.
Table 3 shows the relationship between clinico-
pathological factors of PC patients and overall survival 
(OS), using Kaplan–Meier method and log rank test. 
Univariate analysis identified PS, UICC stage, patho-
logical T and N stages, P-CRP, and carbohydrate anti-
gen 19-9 (CA19-9) as significant predictors of OS, while 
other factors such as age, sex, BMI, tumor location, 
preoperative infection, NAC, AC, PVR, R0 resection, 
histology, POPF, postoperative complication, and carci-
noembryonic antigen (CEA) were not significant.
CA19-9, which is one of the most common tumor 
markers with regards to prognosis in PC, had no sig-
nificant correlation with P-CRP (Fig. 2). Multivariate 
analysis revealed that the independent risk factors for 
OS were pN stage, P-CRP and CA19-9 (Table 4).
To evaluate the relationship between postopera-
tive changes in P-CRP and prognosis, 103 PC patients 
whose postoperative data were available were classified 
into four groups, namely P-CRPLow-Down, P-CRPLow-Up, 
P-CRPHigh-Down and P-CRPHigh-Up, based on postop-
erative changes in P-CRP compared to preoperative 
P-CRP. Next, survival analysis in the four groups, 
performed using the Kaplan–Meier method, showed 
that prognosis (as OS) was significantly different among 
these four groups (Fig. 3, P = 0.012).
DISCUSSION
Here, we have evaluated the prognostic value of P-CRP 
in patients who had undergone surgery for PC using a 
preoperative cut-off value of 1.782, determined by ROC 
analysis, because the AUC value for P-CRP was greater 
than that of either platelet or CRP (0.67 vs. 0.51, 0.66). 
This observation implies that the combination of platelet 
and CRP can better predict the prognosis in PC patients.
CA19-9, which is a substance elevated in many PC 
patients and one of the most common tumor markers 
with regards to prognosis in PC (as shown in Fig. 1), 
had no significant correlation with P-CRP. This result 
suggests that CA19-9 and P-CRP are independent pre-
dictors from each other.
As Table 2 shows, patients in the P-CRPHigh 
group underwent significantly longer procedures and 
experienced greater blood loss compared to those in the 
P-CRPLow group. P-CRPHigh group had longer operation 
time and greater blood loss than P-CRPLow group with 
statistical significance. These differences may have 
been caused by endogenous inflammatory conditions of 
tumor6 in the P-CRPHigh group, such as fibrotic changes 
or greater bleeding tendency, which can make the 
procedure more difficult. Additionally, the presence of 
preoperative biliary infection did not differ significantly 
between the two groups, suggesting that preoperative 
inflammation might predominantly originate from the 
tumors themselves. Furthermore, tumor location had no 
relation to P-CRP as well as OS (Tables 2 and 3).
Univariate analysis revealed that P-CRPHigh 
patients had a significantly poorer prognosis than 
P-CRPLow patients, and multivariate analysis showed 
that P-CRP was an independent predictor of OS in PC 
patients. Furthermore, we hypothesized that postopera-
tive P-CRP value may affect the prognosis of PC and 
analyzed the prognosis of four groups according to 
preoperative P-CRP and postoperative alteration of the 
value; P-CRPLow-Down, P-CRPLow-Up, P-CRPHigh-Down 
and P-CRPHigh-Up.
The Kaplan-Meier method showed differences 
with statistical significance between four groups. This 
indicates the postoperative P-CRP may offer further 
significance of the prognosis in both P-CRPHigh and 
P-CRPLow groups. These results suggest that preopera-
tive inflammatory state and levels of prolonged post-
operative inflammation can affect cancer malignancy, 
including metastasis and local recurrence after surgery.
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Table 1. Patient characteristics
n = 107
Age (years) 71.1 ± 8.4
Sex Male 68
Female 39




Tumor location Head 67
Body/Tail 40












Others (including IPMC) 21




N stage N1 58
N0 49
Vascular invasion Yes 87
No 20
Perinural invasion Yes 90
No 17




Operation time (h) 7.72 ± 2.48





POPF ≥ grade B Yes 26
No 81
Complication CD ≥ 2 Yes 36
No 71
AC, adjuvant chemotherapy; BMI, body mass index; CD, Clavien-Dindo Classification; NAC, neoadjuvant chemotherapy; PDAC, 
pancreatic ductal adenocarcinoma; POPF, postoperative pancreatic fistula; PS, performance status; PVR, portal vein resection.
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This study has a few limitations in that it is a 
single-institution, retrospective study, with a small 
sample size. Nevertheless, as there are very few studies 
that have focused on the relation of both pre/postopera-
tive P-CRP values and prognosis in PC patients, the 
results presented here may help categorize the patients 
who undergo surgery into high/low risk–groups with 
respect to OS.
To summarize, this study revealed that pre- and 
post-operative inf lammation can be strengthened 
with P-CRP and predict the prognosis in PC patients. 
Therefore, the role of inflammation-based factors such 
as P-CRP should be verified by future large-scale clini-
cal studies.
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Fig. 1. ROC curves and AUC for P-CRP, platelet, CRP and CA19-9.
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Table 2. Comparison of clinicopathological factors between two groups
P-CRP < 1.782 ≥ 1.782
n = 49 n = 58 P value
Age (years) 72 ± 8.1 73.5 ± 8.6 0.53
Sex Male 29 39
0.43
Female 20 19
BMI (kg/m2) 21.4 ± 3 21.9 ± 3.18 0.26
PS 0 33 36
0.69
1/2 16 22
Tumor location Head 28 39
0.32
Body/Tail 21 19
Preoperative Infection Yes 3 10
0.14
No 46 48
NAC Yes 6 7
1
No 43 51
AC Yes 25 29
1
No 24 29
Operation time (h) 7.5 ± 2.5 8.3 ± 2.4 0.047*
Blood loss (g) 390 ± 569 578 ± 587 0.028*
PVR Yes 12 11
0.64
No 37 47
R0 Yes 42 48
0.79
No 7 10
Stage 0/I/II 48 57
1
III/IV 1 1
Histology PDAC 40 46
0.81
Others (including IPMC) 9 12
T stage Tis/1/T 9 6
0.27
3/4 40 52
N stage N0 27 22
0.084
N1 22 36
Vascular invasion Yes 38 49
0.46
No 11 9
Perinural invasion Yes 40 50
0.6
No 9 8
Lympho invasion Yes 3 10
0.14
No 46 48
POPF ≥ grade B Yes 8 18
0.11
No 41 40




AC, adjuvant chemotherapy; BMI, body mass index; CD, Clavien-Dindo Classification; NAC, neoadjuvant chemotherapy; PDAC, 
pancreatic ductal adenocarcinoma; POPF, postoperative pancreatic fistula; PS, performance status; PVR, portal vein resection.
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Table 3. Relationships between clinicopathological factors and OS in PC patients
n 5Y survival (%) MST (year) P value
Age (years) < 65 23 40 3.11
0.61
≥ 65 84 28 2.38
Sex Female 39 38 3.11
0.1
Male 68 26 2.37
BMI < 25 92 31 2.38
0.63
≥ 25 15 27 3.11
PS 0 69 36 3.11
0.0018*
1/2 38 20 1.37
Tumor location Head 67 33 2.93
0.96
Body/Tail 40 26 2.38
Preoperative Infection 0 94 31 2.48
0.53
1 13 <NA> 2.05
NAC Yes 13 34 3.30
0.64
No 94 30 2.38
AC Yes 54 27 2.48
0.68
No 53 34 2.48
Operation time ≤ 8 h 58 35 1098
0.091
> 8 h 49 25 798
Blood loss ≤ 500 g 55 36 1190
0.05
> 500 g 52 25 798
PVR Yes 23 37 2.37
0.96
No 84 29 2.48
R0 Yes 90 29 2.48
0.68
No 17 <NA> 1.72
UICC 0 /I/II 105 31 2.48
0.025*
III/IV 2 <NA> 0.98
Histology PDAC 86 29 2.48
0.96
Others (including IPMC) 21 46 2.38
pT Tis/1/2 15 75 <NA>
0.0045*
3/4 92 25 2.33
pN 0 49 52 10.07
< 0.001*
1 58 12 1.52
POPF ≥ grade B Yes 26 47 3.62
0.19
No 81 25 2.37
complication CD ≥ 2 Yes 36 26 2.38
0.3
No 71 39 3.30
P-CRP ≤ 1.782 49 38 3.26
0.019*
> 1.782 58 24 2.15
CEA (ng/mL) < 5 81 32 2.93
0.092
≥ 5 26 26 1.27
CA19-9 (U/mL) < 35 50 36 3.11
0.021*
≥ 35 57 26 1.83
*Statistically significant. 
5Y survival, 5 year survival; AC, adjuvant chemotherapy; BMI, body mass index; CD, Clavien-Dindo Classification; IPMC, intraductal 
papillary mucinous carcinoma; MST, median survival time; NA, not applicable; NAC, neoadjuvant chemotherapy; OS, overall survival; 
PC, pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma; POPF, postoperative pancreatic fistula; PS, performance status; PVR, 
portal vein resection.
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